Clinical trials
Cholangiocarcinoma Resectable clinical trials
Below are recruiting cholangiocarcinoma resectable clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06923475RecruitingPhase 2/Phase 3
Chemo plus immunotherapy before surgery for bile duct cancer
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
AmsterdamAges 18 years+ - NCT06850753Recruiting
En bloc removal of liver and pancreas with transplant for bile duct cancer
This trial tests a new surgical approach that removes the liver, pancreas, and bile duct all at once (and then gives a liver transplant) for people with a type of bile duct cancer that cannot be removed with standard surgery. It may help people whose cancer is limited to the liver area and who have not responded to other treatments.
OsloAges 18–70 - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT06997913Enrolling by invitation
Immunotherapy and chemoradiation after bile duct cancer surgery
This trial tests whether combining immunotherapy with chemotherapy and radiation after surgery can help prevent bile duct cancer from coming back in people who have a high risk of recurrence.
XiAn, ShanxiAges 18–70 - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT06607276RecruitingPhase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
Nanjing, JiangsuAges 18–75 - NCT05967182RecruitingPhase 2
Pembrolizumab plus chemo before or around liver surgery
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Houston, TexasAges 18 years+ - NCT06406816RecruitingEarly Phase 1
Vaccine and chemotherapy after surgery for bile duct cancer
This trial tests a personalized cancer vaccine combined with chemotherapy to help prevent bile duct cancer from coming back after surgery. It is for people who had their tumor removed but have a high risk of recurrence.
Fuzhou, FujianAges 18–75 - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT06721286RecruitingPhase 2
Combining immunotherapy with chemotherapy before surgery for bile duct cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07619313RecruitingPhase 1
AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer
This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT03364530RecruitingPhase 2
Liver artery chemotherapy for non-surgical bile duct cancer
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
AmiensAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT06313203RecruitingPhase 2
Chemotherapy with or without liver-directed treatment for bile duct cancer
This trial tests whether adding a liver-directed treatment (HAI floxuridine or SIRT) to standard chemotherapy (GemOx) is more effective for people with bile duct cancer inside the liver that cannot be removed by surgery. It may be an option for those whose cancer is only in the liver or nearby lymph nodes.
Oslo, OsloAges 18 years+ - NCT06098547Recruiting
Liver transplant for bile duct cancer that can't be removed
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. You must have had at least six months of chemotherapy and your cancer must be stable or smaller before you can be listed for a transplant.
PadovaAges 18–70 - NCT06730009RecruitingPhase 1/Phase 2
NK cell therapy after surgery for pancreatic or bile duct cancer
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
TainanAges 18 years+ - NCT04078230Recruiting
Extending lymph node removal during liver tumor surgery
This study looks at whether removing more lymph nodes while surgically removing an intrahepatic cholangiocarcinoma (bile duct cancer in the liver) improves outcomes. It may help by better checking and treating possible microscopic spread to lymph nodes.
Baltimore, MarylandAges 18–80 - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06050252RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk bile duct cancer
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
Irvine, CaliforniaAges 18 years+ - NCT04556214Recruiting
Liver transplant test for certain bile duct cancers
This trial studies whether a liver transplant can help people with a non-removable type of bile duct cancer in the liver. To be eligible, the cancer must be in the liver only (no spread), and you typically must already have had at least 6 months of treatment before being listed for transplant.
OsloAges 18 years+ - NCT06208462RecruitingPhase 2
Combination therapy before surgery for high-risk bile duct cancer
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Nanjing, JiangsuAges 18–75 - NCT06125769Recruiting
Liver transplant for hard-to-treat bile duct cancer
This trial studies liver transplantation to treat a specific bile duct cancer (perihilar cholangiocarcinoma) that cannot be removed by surgery. It aims to see if a transplant can help when standard chemotherapy has kept the cancer stable.
Padova, PADOVAAges 18–70 - NCT06296563RecruitingPhase 2
Testing adebrelimab, apatinib, and HAIC for bile duct cancer
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Jinan, ShandongAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma resectable?
- Yes. Clin2 currently lists 31 recruiting cholangiocarcinoma resectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma resectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma resectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.